NANOBIOTIX SA - ADR
Nanobiotix SA (ADR: NBTX) is a clinical-stage biotechnology company focused on physics-based therapeutics that enhance radiotherapy for solid tumours. Its lead candidate, NBTXR3 (marketed as Hensify in some jurisdictions), are tumour-injected crystalline nanoparticles designed to amplify the local effect of ionising radiation. The company is headquartered in France and listed as an American Depositary Receipt in the US, with multiple Phase II/III programmes and investigator-led studies across indications such as soft-tissue sarcoma and head and neck cancers. As a clinical-stage stock, progress is driven by trial outcomes, regulatory decisions and partnership or commercial execution; revenues are limited and further financing may be required. Market capitalisation is about $1.13bn. This summary is educational only and not personalised investment advice — suitability depends on your circumstances. Remember values can rise and fall and returns are not guaranteed.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying NANOBIOTIX stock, expecting it to rise to $17.4 soon.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NBTX
Cancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Several ongoing trials may provide meaningful data points that could de‑risk the story, though outcomes are binary and timelines can be long.
Physics-based approach
NBTXR3 amplifies radiotherapy locally and may complement existing cancer treatments; adoption depends on convincing clinical evidence and regulatory acceptance.
Commercial and funding
Limited commercial approvals and partnerships could support growth, but rollout complexity and potential funding needs are important considerations for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
